Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial
| Image |  |
|---|---|
| Description | scientific article published on 08 April 2019 |
| Author/s |
author: Einat Brill-Almon Raul Chertkoff Sari Alon Raphael Schiffmann |
| Publication date | April 8, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |